daratumumab,talquetamab,teclistamab
genmab,janssen,merck
['talquetamab', 'tecvayli']
first combination therapy using 2 bispecific antibodies, tecvayli (bcma targeted) and talquetamab (gprc5d targeted). 96% overall response rate, comparable to car t therapies. #asco23 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.